Winning Health(SZ:300253)2025-04-27 13:30Group 1: Financial Performance - In 2024, the company achieved a revenue of CNY 2.782 billion, a decrease of 12.05% year-on-year [2] - Net profit attributable to shareholders was CNY 88 million, down 75.45% year-on-year; net profit excluding non-recurring items was CNY 124 million, down 62.66% [2] - Core software and service revenue was CNY 2.152 billion, a decline of 9.25%; hardware revenue was CNY 293 million, down 38.57%; internet healthcare revenue was CNY 337 million, an increase of 7.83% [2] - In Q1 2025, revenue was CNY 345 million, a decrease of 30.24%; net profit attributable to shareholders was CNY 5.289 million, down 68.18% [3] Group 2: Cost Management and Cash Flow - The company implemented cost control measures, resulting in a combined decrease of 17.94% in sales, management, and R&D expenses [3] - Cash flow from operating activities reached CNY 408 million, a year-on-year increase of 120.53% [3] - In Q1 2025, the combined decrease in sales, management, and R&D expenses was 28.39% [3] Group 3: Product Development and AI Integration - The company focused on its core product WiNEX, with successful international projects like the Macau Concordia Hospital [3] - In 2024, R&D investment was CNY 562 million, accounting for 20.21% of revenue [3] - By March 2025, over 100 users had deployed the medical large model and AI applications [3] Group 4: Future Plans and Market Strategy - The company plans to expand its AI subscription model, having launched 9 AI subscription packages covering 18 scenarios [4] - The company aims to enhance customer engagement and increase the number of paying customers for AI services [4] - There are no current plans for share buybacks or increases, but future actions will be disclosed as necessary [5]